Post-Exposure Prophylaxis with Favipiravir among Household Close Contacts to Confirmed COVID-19 cases: Cluster-Randomized Trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210909002

Enrollment

156

Registered

2021-09-09

Start date

2021-09-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Household contacts with SARS-CoV-2 index case Favipiravir, post-exposure prophylaxis, household, Favipiravir solution, COVID-19, SARS-CoV-2

Interventions

The 1600 mg/ day of Favipiravir tablets or solution were assigned to a randomized family cluster (1: 1) for 7 days. Dose adjustment to obesity household contacts is 2000 mg/day.,Standard protocol and

Active Comparator Drug,No Intervention No treatment

Favipiravir tablets or solution post exposure prophylaxis group,No post exposure prophylaxis group

Eligibility

Sex/Gender

All

Age

7 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. age equal or more than 7-year-old 2. Close contact with SARS-CoV-2 index case confirmed with SARS-CoV-2 PCR 3. Contact with index case less than 72 hours before enrollment 4. Comminacability by electronic module

Exclusion criteria

Exclusion criteria: 1. Household contacts who have symptoms compatible with SARS-CoV-2 infection definition or SARS-CoV-2 PCR showed a positive result. 2. Previous receiving favipiravir in 14 days 3. Contraindication of favipiravir treatment 4. Pregnancy in any trimester 5. Allergy to favipiravir 6. Moderate to severe liver disease

Design outcomes

Primary

Measure	Time frame
Proportion of SARS-COV-2 infection in household contacts between favipiravir PEP group compred with no treatment group 14 days Proportion/ Odd ratio/ Relative Risk Reduction	—

Secondary

Measure	Time frame
Proportion of SARS-COV-2 infection in household contacts between favipiravir PEP group compred with no treatment group 28 days Proportion/ Odds ratio/ Relative risk reduction,Hospitalization rate and mortality of SARS-COV-2 infection in household contacts between favipiravir PEP group compred with no treatment group 28 days Proportion,Severity of SARS-COV-2 infection in household contacts between favipiravir PEP group compred with no treatment group 14 days Proportion,Rate of favipiravir cessation in participants 14 days Number, percent,Adherene of favipiravir tablets compared with favipiravir solutions 7 days Proportion,Adverse events of favipiravir tablets and solutions 14 days proportion	—

Measure

Time frame

Proportion of SARS-COV-2 infection in household contacts between favipiravir PEP group compred with no treatment group 28 days Proportion/ Odds ratio/ Relative risk reduction,Hospitalization rate and mortality of SARS-COV-2 infection in household contacts between favipiravir PEP group compred with no treatment group 28 days Proportion,Severity of SARS-COV-2 infection in household contacts between favipiravir PEP group compred with no treatment group 14 days Proportion,Rate of favipiravir cessation in participants 14 days Number, percent,Adherene of favipiravir tablets compared with favipiravir solutions 7 days Proportion,Adverse events of favipiravir tablets and solutions 14 days proportion

—

Countries

Thailand

Contacts

Public ContactTaweegrit Siripongboonsitti

Chulabhorn Hospital, Chulabhorn Royal Academy

taweegrit.sir@pccms.ac.th66816924872

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026